Kuo, James C; Parakh, Sagun; Yip, Desmond
What is known and objective Regorafenib improves progression-free survival as a late-line treatment for patients with metastatic gastrointestinal stromal tumour (GIST). As a multitargeted tyrosine kinase inhibitor (TKI), the expected adverse events of regorafenib are similar to those reported with imatinib, sunitinib or sorafenib. We report the first case of hyperammonemic encephalopathy related to regorafenib in a patient with metastatic GIST. Case summary A 61-year-old man maintained on...[Show more]
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.